Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
17
MBX.TO Quote, Financials, Valuation and Earnings
Last price:
$0.22
Seasonality move
:
30.41%
Day range:
$0.22 - $0.22
52-week range:
$0.21 - $0.55
Dividend yield:
0%
P/E ratio:
25.45x
P/S ratio:
1.61x
P/B ratio:
1.08x
Volume:
61.9K
Avg. volume:
57.4K
1-year change:
-41.89%
Market cap:
$29.9M
Revenue:
$18.6M
EPS (TTM):
-$0.02
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Microbix Biosystems, Inc. has 132.56% upside to fair value with a price target of $0.50 per share.
MBX.TO vs. S&P 500
-
Over the past 5 trading days, Microbix Biosystems, Inc. has underperformed the S&P 500 by -12.34% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Microbix Biosystems, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Microbix Biosystems, Inc. revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Microbix Biosystems, Inc. reported revenues of $3.7M.
Earnings Growth
-
Microbix Biosystems, Inc. earnings have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter Microbix Biosystems, Inc. reported earnings per share of -$0.01.
Enterprise value:
24.5M
EV / Invested capital:
--
Price / LTM sales:
1.61x
EV / EBIT:
44.33x
EV / Revenue:
1.32x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-27.97x
Price / Operating cash flow:
17.13x
Enterprise value / EBITDA:
128.23x
Gross Profit (TTM):
$9.9M
Return On Assets:
-5.84%
Net Income Margin (TTM):
-12.08%
Return On Equity:
-7.73%
Return On Invested Capital:
-6.35%
Operating Margin:
-37.58%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $16.5M | $25.4M | $18.6M | $6.3M | $3.7M | |
| Gross Profit | $7.5M | $15.4M | $9.9M | $3.5M | $1.5M | |
| Operating Income | -$2.7M | $3.9M | -$1.6M | $710.8K | -$1.4M | |
| EBITDA | -$1.6M | $5.5M | $191.4K | $1.1M | -$935.5K | |
| Diluted EPS | -$0.00 | $0.03 | -$0.02 | $0.00 | -$0.01 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $19.1M | $22.4M | $22.3M | $24.3M | $23.6M | |
| Total Assets | $28.8M | $33.1M | $35.7M | $38.1M | $37.4M | |
| Current Liabilities | $5.2M | $2.7M | $4.3M | $3.4M | $2.8M | |
| Total Liabilities | $10.3M | $8.2M | $11M | $9.8M | $9.6M | |
| Total Equity | $18.6M | $24.9M | $24.6M | $28.3M | $27.8M | |
| Total Debt | $7.7M | $5.8M | $6.6M | $6.4M | $6.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$1.1M | $4.3M | -$80.3K | $765.9K | $84K | |
| Cash From Investing | -$1M | -$1.9M | -$797.3K | -$229.5K | -$154.3K | |
| Cash From Financing | $229.2K | -$1.1M | $27K | -$381.9K | $82.2K | |
| Free Cash Flow | -$2.1M | $2.4M | -$877.6K | $536.4K | -$70.3K | |
MBX.TO
Sector
Market Cap
$29.9M
$27.9M
Price % of 52-Week High
39.09%
51.04%
Dividend Yield
0%
0%
Shareholder Yield
-3.15%
-1.49%
1-Year Price Total Return
-41.89%
-16.66%
Beta (5-Year)
0.504
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.23
200-day SMA
Sell
Level
$0.30
Bollinger Bands (100)
Sell
Level
0.23 - 0.27
Chaikin Money Flow
Buy
Level
26.3M
20-day SMA
Sell
Level
$0.24
Relative Strength Index (RSI14)
Sell
Level
35.26
ADX Line
Sell
Level
16.19
Williams %R
Buy
Level
-88.8889
50-day SMA
Sell
Level
$0.25
MACD (12, 26)
Sell
Level
-0.01
25-day Aroon Oscillator
Sell
Level
-92
On Balance Volume
Neutral
Level
8.7M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.0088)
Buy
CA Score
(Annual)
Level (0.6543)
Buy
Beneish M-Score
(Annual)
Level (-3.2391)
Sell
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-1.3532)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Microbix Biosystems, Inc. engages in developing and commercializing proprietary biological and technology solutions for human health and wellbeing. It operates through the Antigens, QAPs and DxTM, and Other segments. The Antigens, QAPs and DxTM segment includes the development, manufacturing and sales of products relating to the medical diagnostics industry. The Other segment deals with the development and commercialization of novel and proprietary products or technologies such as Kinlytic. The company was founded by William J. Gastle in 1988 and is headquartered in Mississauga, Canada.
Stock Forecast FAQ
In the current month, MBX.TO has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MBX.TO average analyst price target in the past 3 months is $0.50.
-
Where Will Microbix Biosystems, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Microbix Biosystems, Inc. share price will rise to $0.50 per share over the next 12 months.
-
What Do Analysts Say About Microbix Biosystems, Inc.?
Analysts are divided on their view about Microbix Biosystems, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Microbix Biosystems, Inc. is a Sell and believe this share price will drop from its current level to $0.50.
-
What Is Microbix Biosystems, Inc.'s Price Target?
The price target for Microbix Biosystems, Inc. over the next 1-year time period is forecast to be $0.50 according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MBX.TO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Microbix Biosystems, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of MBX.TO?
You can purchase shares of Microbix Biosystems, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Microbix Biosystems, Inc. shares.
-
What Is The Microbix Biosystems, Inc. Share Price Today?
Microbix Biosystems, Inc. was last trading at $0.22 per share. This represents the most recent stock quote for Microbix Biosystems, Inc.. Yesterday, Microbix Biosystems, Inc. closed at $0.22 per share.
-
How To Buy Microbix Biosystems, Inc. Stock Online?
In order to purchase Microbix Biosystems, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get MBX.TO Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
MBX.TO
Sector
P/E ratio
25.45x
23.85x
PEG ratio
0.00x
-0.01x
P/B ratio
1.08x
1.81x
Price / LTM sales
1.61x
1.58x
Growth Metrics
MBX.TO
Sector
Revenue growth
-40.51%
4.62%
Earnings growth
-431.25%
10.5%
Revenue (5-year growth)
12.05%
6.5%
Earnings forecast
--
-$0.21
Profitability
MBX.TO
Sector
Profitability FY 2025
$9.9M
$3.6M
Return on invested capital
-6.35%
-31.87%
Return on assets
-5.84%
-28.18%
Return on equity
-7.73%
-37.63%
Earnings Date
Last Earnings Date
Dec
21
Next Earnings Date
Dec
21
Estimated Next Earnings Date
Mar
22
Balance Sheet
MBX.TO
Sector
Total cash
$12.1M
$26.4M
Short term investments
--
$25.7M
Total assets
$37.4M
$76.9M
Long term debt
$6.8M
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
